This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1989 Apr;25(4):755-7.

doi: 10.1016/0277-5379(89)90216-2.

Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group

J F Smyth¹, S Gundersen, J Renard, H M Pinedo

Affiliations

PMID: 2714350
DOI: 10.1016/0277-5379(89)90216-2

Clinical Trial

Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group

J F Smyth et al. Eur J Cancer Clin Oncol. 1989 Apr.

. 1989 Apr;25(4):755-7.

doi: 10.1016/0277-5379(89)90216-2.

Authors

J F Smyth¹, S Gundersen, J Renard, H M Pinedo

Affiliation

¹ Department of Clinical Oncology, Western General Hospital, Edinburgh, Scotland, U.K.

PMID: 2714350
DOI: 10.1016/0277-5379(89)90216-2

No abstract available

PubMed Disclaimer

Similar articles

Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H, Gjedde SB, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen HT. Nolte H, et al. Eur J Cancer Clin Oncol. 1989 Apr;25(4):655-7. doi: 10.1016/0277-5379(89)90201-0. Eur J Cancer Clin Oncol. 1989. PMID: 2714342
TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
Van Oosterom AT, Droz JP, Fossa ST, Bono AV, Splinter TA, Verbaeys AJ, Keizer J, De Pauw M, Sylvester R. Van Oosterom AT, et al. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1889-90. doi: 10.1016/0277-5379(89)90365-9. Eur J Cancer Clin Oncol. 1989. PMID: 2632270 No abstract available.
A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung.
Vibe-Petersen J, Bach F, Pedersen AG, Smyth J, Hansen HH. Vibe-Petersen J, et al. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1881-5. doi: 10.1016/0277-5379(89)90363-5. Eur J Cancer Clin Oncol. 1989. PMID: 2561100 No abstract available.
TCNU: a ray of hope for designer nitrosoureas?
Workman P. Workman P. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1823-8. doi: 10.1016/0277-5379(87)90046-0. Eur J Cancer Clin Oncol. 1987. PMID: 3325292 Review. No abstract available.
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
Khayat D, Cour V, Bizzari JP, Aigner K, Borel C, Cohen-Alloro G, Weil M, Auclerc G, Buthiau D, Bousquet JC, et al. Khayat D, et al. Am J Clin Oncol. 1991 Oct;14(5):400-4. doi: 10.1097/00000421-199110000-00008. Am J Clin Oncol. 1991. PMID: 1951178 Review.

See all similar articles

Cited by

Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
Huseman ED, Lo A, Fedorova O, Elia JL, Gueble SE, Lin K, Sundaram RK, Oh J, Liu J, Menges F, Rees MG, Ronan MM, Roth JA, Batista VS, Crawford JM, Pyle AM, Bindra RS, Herzon SB. Huseman ED, et al. J Am Chem Soc. 2024 Jul 10;146(27):18241-18252. doi: 10.1021/jacs.3c06483. Epub 2024 May 30. J Am Chem Soc. 2024. PMID: 38815248 Free PMC article.
A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression.
Shervington L, Ingham O, Shervington A. Shervington L, et al. RSC Adv. 2020 May 6;10(30):17561-17570. doi: 10.1039/d0ra02686g. eCollection 2020 May 5. RSC Adv. 2020. PMID: 35515578 Free PMC article.
A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.
McKeage M, Dady P, Clear M, MacDonald A. McKeage M, et al. Cancer Chemother Pharmacol. 1992;29(3):201-6. doi: 10.1007/BF00686253. Cancer Chemother Pharmacol. 1992. PMID: 1733552

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information